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Background:  Counterfeit and substandard 
medicines are a threat to health and the risks they 
13
pose have been largely underestimated to date.  
Almost all areas of the world are affected by the 
availability of substandard and counterfeit 
medicines, but mounting evidence shows that the 
problem is disproportionately severe in developing 
and emerging market countries, which also have a 
5,12
high burden of infectious diseases.  In poor 
countries, essential and life-saving drugs used to 
treat infectious diseases such as tuberculosis and 
3
malaria are often the drugs under threat. 
Methodology:  This was a cross sectional study 
whose objective was to determine the quality of 3 
types of fixed dose combination (FDC) anti TB 
drugs namely 4FDC, 3FDC and 2FDC tablets 
available in Lusaka District by assessing the 
presence of active ingredients and the percentage 
content of these active ingredients according to the 
B r i t i s h  p h a r m a c o p o e i a  2 0 0 8  u s i n g  
Spectrophotometric method. The drug samples 
analyzed had a shelf life of at least one year. 
Results: For presence of active ingredient, all the 
seventeen samples that were tested gave a positive 
result indicating that each sample had the correct 
active ingredients as indicated by the label claim. 
However, 20% (1/5) of the 4FDC samples and 14% 
(1/7) of the 2FDC samples were none compliant to 
the BP 2008 specification for percentage content. 
One sample of 4FDC had a percentage content of 
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106.3% for Isoniazid that was above the BP 2008 
specification of 95% to 105% and one sample of 
2FDC had a percentage content of 105.6% for 
Isoniazid that was also above the BP. 2008 
specification of 95% to 105%. 
All the 3FDC samples were compliant to the BP 
2008 specification for percentage content of 95% to 
105%. 
Conclusion:  The results from this study have 
established that substandard fixed dose 
combination anti TB drugs are present in Lusaka 
District. These results confirm the urgent need to 
have a national quality control laboratory that is 
supported by satellite mini laboratories at the points 
of entry for drugs and also to strengthen post 
marketing surveillance of all Pharmaceutical 
products that are imported into the country or 
manufactured locally. This will ensure safety and 
efficacy of the drugs that are used in the country.              
 INTRODUCTION
Fixed dose combination (FDC) anti TB Drugs used 
in Zambia come as imports from other countries and 
Drug quality is currently receiving renewed 
international attention. Counterfeit and substandard 
drugs have been increasingly reported in 
developing countries where drug regulations are 
ineffective. Many factors contribute to the 
increased prevalence of substandard and counterfeit 
medications such as poor quality control during 
1,2,14
manufacture.
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access to these drugs is through the public 
institutions such as the Government run hospitals 
and clinics, the private institutions (hospitals and 
clinics). What is of much concern is that there is 
inadequate post – marketing surveillances on these 
drugs. The consequence of using counterfeit and 
substandard FDC drugs is a high burden of the 
disease leading to toxicity or multi drug resistance 
13tuberculosis, high mortality and morbidity.
Almost all areas of the world are affected by the 
availability of substandard and counterfeit 
medicines, but mounting evidence shows that the 
problem is disproportionately severe in developing 
and emerging market countries, which also have a 
high burden of infectious diseases. In poor 
countries, essential and life-saving drugs used to 
treat infectious diseases such as tuberculosis and 
3malaria are often the drugs under threat.  
Counterfeit and substandard medicines present an 
11enormous public health challenge.  
According to WHO, Substandard drugs do not meet 
official standards for strength, quality, purity and / 
or labeling, and these drugs result in serious health 
implications such as lacking therapeutic effect and 
causing treatment failure, severe adverse effects, 
increased morbidity and mortality, development of 
drug resistance and in the case of TB multi drug 
12
resistance TB and waste of resources.  
It is quite clear from above that the problem of 
counterfeit and substandard anti TB drugs is a 
growing threat to global health and has not spared 
Sub Saharan Africa as shown by studies conducted 
6,7,9
in South Africa and Botswana.  
Substandard drug preparations are present 
11throughout the world.  A study that involved the 
screening of single and fixed dose combination 
(FDC) anti TB drugs from selected TB programs 
from Colombia, Estonia, India, Latvia, Russia and 
Vietnam was done using a method called Thin 
Layer Chromatography (TLC). The results from 
this study showed that a substantial number of anti 
Tuberculosis drugs from several countries, in 
particular FDC were found to be substandard. 10% 
(4/40) of all samples contained less that 85% of 
stated content, 13% (4/30) Rifampicin samples 
contained less than 85% of stated content. The study 
also showed that more FDCs (5/24, 21%) than single 
drug samples (2/16, 13%) were substandard.  Such 
drugs may contribute to the creation of drug 
8
resistant Tuberculosis.  
In 2001 a study was done in Nigeria to check the 
quantity of active ingredients in anti TB drugs and 
the results showed that more than 50% of the anti TB 
drugs failed to comply with the official monographs. 
The tested drugs had low quantities of the active 
10
ingredients.  In 1999, a study was also conducted in 
South Africa that involved screening of FDC 
formulations and the results showed that 70% (7/10) 
of the samples had Rifampicin being non 
bioequivalent to the official monograph and this had 
serious implications on treatment outcomes for TB 
hence the moderately high rate of multi drug 
resistance (MDR) cases that were recorded in the 
9 country.
Another study was done in Botswana in 1999 that 
involved quantitative analysis of 13 FDC anti TB 
samples and the results obtained showed that 31% 
(4/13) of the samples were substandard with 15% 
(2/13) having less than 85% Rifampicin as active 
ingredient, 8% (1/13) having more than 115% of 
Rifampicin and 8% (1/13) of the samples having 
more than 115% Pyrazinamide. The gold standard 
used was Ultra Violet Spectrophotometry with a 
6, 7
sensitivity of 100% and specificity of 90%.  
In Zambia there is no documented evidence about 
any research done to determine the existence of 
substandard FDC anti TB drugs. However, the 
Government of the Republic of Zambia has shown 
its commitment to fight the scourge by establishing 
institutions such as the Pharmaceutical Regulatory 
Authority (PRA) and the Drug Enforcement 
th
Commission (DEC). Furthermore, on 11  
November 2008, the government formed the Drug 
Taskforce to fight counterfeiting of drugs in the 
country. 
The aim of this study was to evaluate the quality of 
fixed dose combination anti TB drugs in Lusaka 
district so as to find ways of strengthening the fight 
against the use of substandard drugs. 





The drugs that were used in the study were anti 
tuberculosis drugs that are used in the treatment of 
TB according to the national tuberculosis treatment 
guidelines for Zambia. These were all fixed dose 
combination drugs that were collected from the 
points of distribution to the patients. Three fixed 
dose combination drugs were used in this study and 
their details are indicated in table 1.
Table 1:  Details of drugs used in the study
Drug quality was assessed by measuring the level of 
active ingredient content as a percentage of stated 
content in the tablet samples in compliance to the 
official monograph. The acceptable levels for each 
drug according to the official monograph (BP 2008) 
are indicated in table 2.
Table 2: Specifications for acceptable levels of each drug 
according to BP. 2008
RESULTS
4FDC
All the four drugs that were contained in 4FDC drug 
samples tested positive to the identification tests and 
the results for the identification tests done on the 
individual drugs contained in 4FDC samples are 
indicated in table 3.
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Isoniazid 95 – 105%
Table 3: Results of identification tests done on 4FDC samples
For percentage content of active ingredient, one 
sample out of five (20%) was not compliant to the 
BP 2008 specification for content of active 
ingredient as a percentage. Sample 1E had 106.3% 
of Isoniazid and fell above the BP 2008 
specification of 95 – 105%. Values of the 
percentage content of active ingredient of the four 
drugs in the assayed 4FDC drug samples are 
indicated in table 4.
Table 4: Percentage content of four drugs in 4FDC samples
3FDC
All the three drugs contained in 3FDC gave a 
positive identification test result for all the five 
samples tested and the identification results of the 
three drugs that were contained in 3FDC samples 
are indicated in table 5.
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Code  




























1D 103.3% 97.6% 98.9% 104.6% Pass
































2D + + + Pass
2E + + + Pass
+= Positive identification test
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All the five samples of 3FDC were found to be 
compliant to the specifications of the BP 2008 for 
percentage content and the values for percentage 
content of the three drugs contained in 3FDC 
samples tested are indicated in table 6.
Table 6: Values of percentage content of the three drugs in 
3FDC samples
2FDC (Rifinah)
The identification tests on the seven samples of 
2FDC drugs showed a 100% positive identification 
test result for all the samples that were tested and the 
test results are indicated in table 7. 
Table 7: Identification test results for individual drugs in 
Rifinah drug samples
However, one out of seven samples (14%) of 2FDC 
was not compliant to the BP 2008 specifications for 
percentage content of active ingredient. Sample 3D 
had 105.6% of Isoniazid and fell above the accepted 









































2E 96.3% 100.5% 103.3% Pass
Drug 
Code  
Rifampicin  Isoniazid  Result  
3A  











































 + = Positive identification test
Table 8: Values of percentage content of the two drugs in 
Rifinah samples
DISCUSSION
This cross sectional study that was conducted in 
Lusaka District to assess the quality of fixed dose 
combination anti Tuberculosis drugs from the 
clinics which are the points of distribution to the 
patients provides vital information on the quality of 
drugs that are being used for the treatment of 
Tuberculosis in the national TB programme. The 
results of the study (table 3 to table 8) provide 
objective information on the quality of drugs in 
terms of presence of active ingredient as well as the 
actual percentage content of each active ingredient 
for each sample that was tested. 
Quality can be defined as a combination of 
attributes of a product which determine its degree of 
acceptability as the right product for the intended 
use and is capable of exerting the correct 
pharmacological action when used correctly. The 
quality of a pharmaceutical product will therefore 
depend on the degree of adherence to the general 
manufacturing practices and the packaging 
materials used to package the product as well as the 
storage conditions that the pharmaceutical product 
is subjected to after manufacture. When any one of 
the above is not addressed adequately the result is a 
pharmaceutical product that is none compliant with 
the official monographs that provide guidance on 
the specifications for quality.
The identification tests for individual drugs that 
were contained in the fixed dose combination 
formulations yielded positive results for all the 
samples that were tested. This means that all the 
Drug 
Code  




































3F 97.9% 103.8% Passed
3G 99.4% 104.2% Passed
samples that were tested yielded a 100% positive 
identification test for the individual components of 
the fixed dose combination formulations in line with 
the label claims of each category of the fixed dose 
combination formulation. All the 4FDC samples 
contained the four drugs indicated on the label and 
these included Pyrazinamide, Ethambutol, 
Rifampicin and Isoniazid. All the 3FDC samples 
contained the three drugs indicated on the label for 
3FDC and these drugs comprised Ethambutol, 
Rifampicin and Isoniazid and the 2FDC samples 
also contained the two drugs as indicated on the 
label which included Rifampicin and Isoniazid.    
The findings of the study on the percentage content 
of active ingredients confirmed the existence of 
substandard fixed dose combination anti TB drugs. 
20% (1/5) of the 4FDC samples and 14% (1/7) of the 
2FDC samples were found to be none compliant to 
the BP 2008 specification for percentage content. 
Isoniazid was found to fall above the BP 
specification of 95 – 105% with a percentage 
content of 106.4% in one sample of 4FDC and 
105.6% in one sample of 2FDC. All the 3FDC 
samples were found to be compliant to the BP 2008 
specifications for percentage content. 
The findings that 20% (1/5) of 4FDC and 14% (1/7) 
of 2FDC did not comply with the BP 2008 
specifications for percentage content entails that 
there is urgent need to strengthen post marketing 
surveillance of all pharmaceutical product with a 
view of improving quality control of for these 
products before they are released to the general 
public for use. The basic aim of these monitoring 
activities is to ensure that all drugs meet the required 
specifications for quality as stipulated in the official 
monographs.  
CONCLUSION
This study has established that substandard anti 
Tuberculosis drugs are present in Lusaka district. 
The results have shown that 20% (1/5) of the 
samples for 4FDC and 14% (1/7) of the samples for 
2FDC were none compliant to the BP 2008 
specifications for percentage content for Isoniazid. 
These results confirm the urgent need to strengthen 
the capacity of the Pharmaceutical Regulatory 
Authority (PRA) to carry out post marketing 
surveillance on all pharmaceutical products that are 
either sold or distributed for free to the general 
public. There is also need for the Ministry of Health 
to establish a national quality control laboratory that 
should be supported by satellite mini laboratories at 
the points of entry for drugs so that quality control on 
drugs can be enhanced. This will ensure safety and 
efficacy of the drugs that are used in the country. 
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